A Model for Communication About Longshot Treatments in the Context of Early Access to Unapproved, Investigational Drugs

Bunnik, Eline M.; Aarts, Nikkie

doi:10.1080/15265161.2017.1401170

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An interview study among medical specialists in The Netherlands, Turkey and the United States (US) reports that accessibility to these programs is hampered by practical constraints, including lack of funding, demands on time and effort, and limited supply. 21 Furthermore, in most countries, including the Netherlands, many other European countries, and the US, there is no routine reimbursement of expanded access. This means that pharmaceutical companies, hospitals, or health insurers would have to pay for the cost of treatment, and neither of them may be willing or able to do so.…”

Section: Ethico-legal Framework In the Netherlandsmentioning

confidence: 99%

Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis

Vermeulen

Hordijk

Visser

et al. 2023

J. Law. Med. Ethics

View full text Add to dashboard Cite

Drawing on ethical and legal frameworks in the Netherlands, the United States and France, we examine whether physicians are expected to inform patients about potentially relevant opportunities for expanded access to investigational drugs. While we found no definitive legal obligation, we argue that physicians have a moral obligation to discuss opportunities for expanded access with patients who have run out of treatment options to prevent inequality, to promote autonomy, and to achieve beneficence.

show abstract

Section: Ethico-legal Framework In the Netherlandsmentioning

confidence: 99%